The Longevity Antioxidant from Mushrooms

How this rare mushroom-derived compound protects cells, supports the aging brain, and is associated with longer life

Ergothioneine is a rare amino acid and antioxidant found almost exclusively in mushrooms — and it may be one of the most overlooked nutrients in the longevity conversation. Unlike most dietary antioxidants, it has its own dedicated transporter in the human gut and bloodstream, meaning the body actively seeks it out and holds onto it. Blood levels naturally decline after age 60, and lower levels are consistently linked to faster cognitive decline, higher cardiovascular risk, and earlier mortality [1][2][5]. Eating mushrooms regularly is the most direct way to raise your ergothioneine levels.

What Makes Ergothioneine Unusual

Most dietary antioxidants are absorbed passively and cleared quickly. Ergothioneine behaves differently. Humans evolved a dedicated membrane transporter — OCTN1 (encoded by the SLC22A4 gene) — that actively pulls ergothioneine from food into the intestinal cells and then reabsorbs it in the kidney to prevent loss through urine [1]. This level of biological investment is rare and suggests the compound plays an important physiological role that evolution has preserved.

Ergothioneine is produced almost exclusively by certain fungi and bacteria — humans and other animals cannot synthesize it and must obtain it entirely from food. Mushrooms, particularly oyster mushrooms and porcini (boletes), are the richest dietary sources, containing 0.4 to 2.0 mg per gram dry weight. Smaller amounts are found in black beans, oat bran, and organ meats like liver and kidney, which accumulate it from fungi in the animal's diet [4].

How It Protects Cells

Ergothioneine works through several complementary mechanisms:

Metal chelation: It binds copper and other transition metals that would otherwise catalyze destructive free radical reactions. This gives it a different and sometimes more potent antioxidant profile than vitamins C and E, which don't chelate metals [1].

Nrf2 activation: It activates Nrf2, the master regulator of cellular antioxidant defense, upregulating the body's own protective enzymes including glutathione peroxidase and superoxide dismutase [4].

Mitochondrial protection: Ergothioneine accumulates in mitochondria — the organelles most exposed to oxidative stress — where it helps preserve energy production and reduces the oxidative damage that drives cellular aging.

Anti-inflammatory effects: It suppresses NF-κB signaling and reduces production of inflammatory cytokines, making it relevant not just to oxidative stress but to the chronic low-grade inflammation associated with aging [1].

How Blood Levels Change with Age and Diet

Plasma ergothioneine levels are primarily determined by how much of it you eat. In populations with low mushroom consumption, ergothioneine levels are measurably lower than in populations that eat mushrooms regularly. Levels also decline with aging — studies in Singapore and Europe have documented that people over 60 have significantly lower plasma ergothioneine than younger adults, and this age-related decline correlates with worsening health outcomes [5].

This creates an interesting possibility: some of the cognitive and cardiovascular decline associated with aging may be partly attributable to declining ergothioneine intake and retention, rather than being purely inevitable.

Food Sources and Supplementation

The best food sources of ergothioneine, ranked roughly by content:

Oyster mushrooms — one of the richest sources (~1.2 mg/g dry weight)
Porcini and other boletes — comparably high
King oyster and shiitake mushrooms — moderate amounts
Common white/cremini mushrooms (Agaricus bisporus) — lower but meaningful
Black beans and red beans — modest amounts
Oat bran — small amounts
Liver and kidney — accumulate ergothioneine from the animal's fungal diet

A 100 g serving of cooked oyster mushrooms provides roughly 5–13 mg of ergothioneine, which appears to meaningfully raise plasma levels. Ergothioneine is heat-stable and survives cooking well, unlike some fragile antioxidants [3].

Supplements are also available, typically as pure ergothioneine (synthetic or from mushroom extract) at 5–25 mg per capsule. An ongoing clinical trial in Singapore is evaluating 25 mg three times weekly for cognitive support in older adults with mild cognitive impairment — the first large RCT of ergothioneine supplementation.

Who Might Benefit Most

People most likely to have low ergothioneine levels:

Those who rarely eat mushrooms
Older adults (especially over 60)
People with chronic inflammatory conditions
Those with cardiovascular risk factors

For most people, increasing mushroom consumption is the simplest, most evidence-grounded approach. If you're eating mushrooms two to three times per week, you're likely getting meaningful ergothioneine exposure.

Cross-reference: For related antioxidants with longevity evidence, see our PQQ page and glutathione page. For the broader context of oxidative stress and aging, see our telomeres page. For the mushrooms themselves, see our medicinal mushrooms section.

Evidence Review

Biology and Mechanisms: Borodina et al. 2020

The most comprehensive overview of ergothioneine biology is the 2020 review by Borodina et al. in Nutrition Research Reviews (PMID 32051057), covering everything from biosynthesis by fungi to human transport, tissue distribution, and mechanisms of cytoprotection. The paper establishes several important points: OCTN1 is expressed not just in the gut but in high-stress tissues including the liver, kidneys, bone marrow, and central nervous system — exactly the organs where ergothioneine accumulates most. The transporter-based accumulation means ergothioneine builds up in tissues over time with regular dietary intake rather than being rapidly cleared.

The review also addresses why ergothioneine is reduced in multiple chronic diseases — rheumatoid arthritis, Crohn's disease, cardiovascular disease, cognitive impairment — without determining causality. Whether low ergothioneine is a cause or consequence of these conditions remains an open question, but the consistent directional association across diseases is compelling. Importantly, ergothioneine has been approved as safe by the FDA (GRAS status) and the European Food Safety Authority, and no adverse effects have been observed in any human or animal study at any dose tested.

Cardiovascular Mortality Study: Smith et al. 2020

The landmark population study was published in Heart by Smith and colleagues (PMID 31672783), using data from the Malmö Diet and Cancer study — a prospective Swedish cohort of 3,236 adults without cardiovascular disease or diabetes at baseline, followed for a median of 21.4 years. Plasma metabolites were profiled at enrollment using untargeted mass spectrometry, and ergothioneine emerged as the metabolite most strongly associated with a healthy dietary pattern.

Over the follow-up period:

603 participants developed cardiovascular disease
362 developed diabetes mellitus
843 died

Higher plasma ergothioneine at baseline was independently associated with lower risk of all three outcomes, even after adjustment for other cardiovascular risk factors:

Coronary disease: HR 0.85 per SD increment (p = 0.01)
Cardiovascular mortality: HR 0.79 per SD (p = 0.002)
Overall mortality: HR 0.86 per SD (p < 0.0001)

The effect size for cardiovascular mortality (21% lower risk per standard deviation increase) is clinically meaningful. The authors cautioned that the association may partly reflect overall dietary quality, since ergothioneine tracks closely with mushroom and plant food intake. However, the dose-response relationship and independent statistical associations suggest ergothioneine itself — not merely diet quality — may be contributing.

Cognitive Decline: Wu et al. 2022

Wu, Kan, Cheah et al. (PMID 36139790) followed 470 elderly adults attending memory clinics in Singapore, measuring plasma ergothioneine and cognitive performance at baseline and across multiple follow-up visits. Participants with lower plasma ergothioneine at baseline showed:

Worse baseline performance across memory, executive function, attention, visuomotor speed, and language
Faster subsequent decline in global cognition and functional ability over follow-up

The associations held after adjustment for age, education, vascular risk factors, and APOE genotype. The authors proposed that ergothioneine may protect the brain through multiple mechanisms — antioxidant defense in neurons and supporting cells, mitochondrial preservation, and anti-neuroinflammatory effects. This observational study cannot prove causation, but it adds to a consistent body of evidence linking ergothioneine levels to brain aging outcomes in humans.

Bioavailability from Mushrooms: Weigand-Heller et al. 2012

The human bioavailability study by Weigand-Heller, Kris-Etherton, and Beelman (PMID 22230474) examined ten healthy men in a randomized, cross-over design. Participants consumed different doses of Agaricus bisporus (white button mushrooms) while blood ergothioneine was measured in red blood cells at multiple time points. Ergothioneine was clearly bioavailable — red blood cell levels increased measurably and dose-dependently after mushroom consumption. An unexpected finding was that mushroom consumption was associated with an attenuated postprandial triglyceride response, hinting at broader cardiometabolic effects. This pilot study confirmed that ergothioneine from ordinary mushrooms reaches the bloodstream in biologically relevant amounts.

Review: Tian, Thorne, and Moore 2023

The 2023 review in the British Journal of Nutrition by Tian et al. (PMID 38018890) synthesized all available evidence and raised a provocative question: should ergothioneine be classified as a conditionally essential micronutrient? The authors reviewed data showing that populations with very low mushroom intake have markedly lower plasma ergothioneine, and that the observed associations between ergothioneine and aging outcomes are consistent across multiple geographical populations and study designs. The paper also highlighted the age-related decline in ergothioneine levels, which occurs independently of dietary changes, possibly due to reduced OCTN1 transporter expression or efficiency in aging gut epithelium. This review positioned ergothioneine alongside taurine and creatine as compounds that are not strictly essential but may become functionally important with age.

Overall Evidence Assessment

The evidence for ergothioneine is strongest in two domains: observational epidemiology (consistent associations with lower CVD and cognitive decline across multiple populations) and mechanistic biology (well-characterized antioxidant and cytoprotective mechanisms). The bioavailability data confirms that food-derived ergothioneine reaches the bloodstream. What is currently limited is interventional human RCT data — this gap is being addressed by ongoing clinical trials. The overall picture supports making ergothioneine-rich foods a regular part of the diet, particularly for adults over 50. The safety profile is excellent, the food sources are delicious, and the epidemiological associations are among the strongest seen for any single dietary compound in the aging literature.

References

The biology of ergothioneine, an antioxidant nutraceuticalBorodina I, Kenny LC, McCarthy CM, et al.. Nutrition Research Reviews, 2020. PubMed 32051057 →
Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular diseaseSmith E, Ottosson F, Hellstrand S, et al.. Heart, 2020. PubMed 31672783 →
The bioavailability of ergothioneine from mushrooms (Agaricus bisporus) and the acute effects on antioxidant capacity and biomarkers of inflammationWeigand-Heller AJ, Kris-Etherton PM, Beelman RB. Preventive Medicine, 2012. PubMed 22230474 →
Ergothioneine: an underrecognised dietary micronutrient required for healthy ageing?Tian X, Thorne JL, Moore JB. British Journal of Nutrition, 2023. PubMed 38018890 →
Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory ClinicsWu LY, Kan CN, Cheah IK, et al.. Antioxidants, 2022. PubMed 36139790 →